Inspra is indicated, in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure (HF) and left ventricular systolic dysfunction. (LVEF ≤30%).1
Inspra (eplerenone) is also indicated, in addition to standard therapy including beta blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF≤40%) and clinical evidence of heart failure after recent myocardial infarction.1
1. Inspra Summary of Product Characteristics.